XGN

Exagen is a credible turnaround story trading at an undemanding price, which is why this is a hold rather than an avoid. Under CEO John Aballi (since Oct 2022) the AVISE autoimmune-diagnostics franchise has been revitalized: FY2025 revenue of $66.6M grew 19.7% — the fastest in the five-year series ($48.3M→$66.6M) — at a healthy 58.3% gross margin, and the MD&A explicitly frames the story as 'a return to revenue growth and gross margin expansion while significantly reducing operating expenses and cash burn.' Operating loss was essentially flat YoY (-$14.1M vs -$13.7M) even as revenue jumped, evidence of real operating leverage. At a $114M market cap the stock changes hands for just 1.7x sales, modest for a profitable-gross-margin diagnostics name growing ~20%.

But the path to actual profitability is unproven and the quality of the business is thin. The company has never earned money — accumulated deficit is -$314M — and the FY2025 net loss widened to -$20.0M (from -$15.1M) for a -30% net margin and -114% ROE. Operating cash flow was -$13.6M; the $32.2M cash pile (up 46%) buys only ~2-2.5 years of runway, and it was funded by heavy dilution — shares outstanding rose 34.4%, so per-share value is being eroded even as the top line grows. The MD&A/Risk Factors flag that the company 'may require substantial additional capital,' meaning more dilution or debt is a live risk.